CTLA4 and cancer: Pruritus is one of the most common cutaneous side effects observed in cancer patients treated with either programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) or T-lymphocyte-associated antigen-4 (CTLA-4) inhibitors [25,29,30].